Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 17, 2023 - Issue
Submit an article Journal homepage
236
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Efficacy and Safety of Anlotinib in Overall and Disease-Specific Advanced Gynecological Cancer: A Real-World Study

Xinyi Hong1 Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, People’s Republic of China
,
Shanhu Qiu2 Department of General Practice, Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, People’s Republic of China
,
Xia Wu3 Department of Gynecological Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu, People’s Republic of China
,
Sizhen Chen4 Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, People’s Republic of China
,
Xiaoxiang Chen5 Department of Gynecological Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-2400-4749
ORCID Icon,
Bei Zhang6 Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, People’s Republic of China
,
Aiqin He3 Department of Gynecological Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, Jiangsu, People’s Republic of China
,
Yun Xu7 Department of Obstetrics and Gynecology, The First People's Hospital of Changzhou, Changzhou, People’s Republic of China
,
Jianqing Wang8 Department of Obstetrics and Gynecology, The Yancheng Clinical College of Xuzhou Medical University, The First People’s Hospital of Yancheng, Yancheng, People’s Republic of China
,
Yingchun Gao9 Department of Obstetrics and Gynecology, Huai’an First People’s Hospital, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China
,
Xizhong Xu10 Department of Obstetrics and Gynecology, The Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China
,
Li Sun11 Department of Gynecological Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, People’s Republic of China
,
Yang Zhang12 Gynecology Department, The First People's Hospital of Lianyungang, Lianyungang, People’s Republic of China
,
Libing Xiang13 Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China
,
Jundong Zhou14 Radio-oncology Department, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People’s Republic of China
,
Qun Guan15 Gynecology Department, Jiangsu Province Hospital of Chinese Medicine, Nanjing, People’s Republic of China
,
Yanling Zhu16 Gynecology Department, Xuzhou Cancer Hospital, Xuzhou, People’s Republic of China
,
Haiyan Liu17 Department of Obstetrics and Gynecology, Affiliated Hospital of Yangzhou University, Yangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0009-0006-3196-5747
ORCID Icon,
Hao Xu18 Gynecology Department, Huangshi Love & Health Hospital Affiliated to Hubei Polytechnic University, Huangshi, People’s Republic of China
,
Ying Zhou19 The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, People’s Republic of China
,
Bingwei Chen4 Department of Epidemiology and Biostatistics, School of Public Health, Southeast University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0159-3699
ORCID Icon &
Yang Shen1 Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1077-7273
ORCID Icon show all
Pages 2025-2033 | Received 12 Feb 2023, Accepted 03 Jun 2023, Published online: 06 Jul 2023

References

  • Yetkin-Arik B, Kastelein AW, Klaassen I, et al. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim Biophys Acta. 2021;1875:188446. doi:10.1016/j.bbcan.2020.188446
  • Inayama Y, Hamanishi J, Matsumura N, et al. Antitumor effect of nivolumab on subsequent chemotherapy for platinum-resistant ovarian cancer. Oncologist. 2018;23:1382–1384. doi:10.1634/theoncologist.2018-0167
  • Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317–2328. doi:10.1200/JCO.19.01009
  • Bamias A, Gibbs E, Khoon Lee C, et al. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. Ann Oncol. 2017;28:1842–1848. doi:10.1093/annonc/mdx228
  • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–2045. doi:10.1200/JCO.2012.42.0505
  • Lee C-H, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021;22:946–958. doi:10.1016/S1470-2045(21)00241-2
  • Jin C, Yuan M, Bu H, et al. Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy. J Oncol. 2022;2022:4880355. doi:10.1155/2022/4880355
  • Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105. doi:10.1186/s13045-016-0332-8
  • Yang H, Sun S, Mei Z, et al. A retrospective cohort study evaluates clinical value of anlotinib in persistent, metastatic, or recurrent cervical cancer after failure of first-line therapy. Drug Des Devel Ther. 2021;15:4665–4674. doi:10.2147/DDDT.S335870
  • Zhu J, Song CY, Zheng Z, et al. Anlotinib in Chinese patients with recurrent advanced cervical cancer: a prospective single-arm, open-label phase II trial. Front Oncol. 2021;11:8. doi:10.3389/fonc.2021.720343
  • Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022;40:1795–1805. doi:10.1200/JCO.21.02091
  • Wei W, Ban X, Yang F, et al. Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 2022;10:e004338. doi:10.1136/jitc-2021-004338
  • Lan C-Y, Zhao J, Yang F, et al. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial. Cell Rep Med. 2022;3:100689. doi:10.1016/j.xcrm.2022.100689
  • Cui Q, Hu Y, Ma D, et al. A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Drug Des Devel Ther. 2021;15:339–347. doi:10.2147/DDDT.S286529
  • Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. J Eur Soc Med Oncol. 2017;28:viii61–viii65. doi:10.1093/annonc/mdx443
  • Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN guidelines insights: cervical cancer, version 1.2020. JNCCN. 2020;18:660–666. doi:10.6004/jnccn.2020.0027
  • Abu-Rustum NR, Yashar CM, Bradley K, et al. NCCN guidelines® insights: uterine neoplasms, version 3.2021. JNCCN. 2021;19:888–895. doi:10.6004/jnccn.2021.0038
  • Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. JNCCN. 2021;19:191–226. doi:10.6004/jnccn.2021.0007
  • Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11:120. doi:10.1186/s13045-018-0664-7

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.